Diabetes mellitus (DM) is a group of metabolic diseases characterised by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. Insulin therapy might be affected by specific metabolic enzymes and transporters. There are conflicting reports in the literature on the role of adenosine receptor A2B (AR2B) in skeletal and cardiac muscle glucose metabolism. This study aims to find out if there is an association between AR2B and insulin signalling, especially the metabolic pathways (AKT-GSK). Differentiated L6 cell rat muscle cells were treated with insulin, adenosine agonist NECA, selective AR2B antagonist PSB 603 and combinations between these reagents, the expression of AKT2, GSK3α, and GSK3β were measured by qPCR hydrolysis probe technique. Insulin increases AKT2, GSK3α and GSK3β mRNA expression, while AR2B antagonist inhibits AKT2 GSK3α and GSK3β mRNA expression and combining AR2B antagonist with insulin diminish insulin action and decrease AKT2 GSK3α and GSK3β mRNA expression, which means a strong relationship between AR2B and insulin action. Furthermore AR2B agonist may be a good candidate as an anti-diabetic drug.

糖尿病（DM）是一组以高血糖为特征的代谢性疾病，由胰岛素分泌缺陷、胰岛素作用缺陷或两者兼而有之。胰岛素治疗可能会受到特定代谢酶和转运蛋白的影响。关于腺苷受体 A2B (AR2B) 在骨骼肌和心肌葡萄糖代谢中的作用，文献中存在相互矛盾的报道。本研究旨在确定 AR2B 与胰岛素信号传导之间是否存在关联，尤其是代谢途径 (AKT-GSK)。用胰岛素、腺苷激动剂NECA、选择性AR2B拮抗剂PSB 603和这些试剂的组合处理分化的L6细胞大鼠肌肉细胞，通过qPCR水解探针技术测量AKT2、GSK3α和GSK3β的表达。胰岛素增加 AKT2、GSK3α 和 GSK3β mRNA 表达，而 AR2B 拮抗剂抑制 AKT2 GSK3α 和 GSK3β mRNA 表达，AR2B 拮抗剂与胰岛素联合使用会降低胰岛素作用并降低 AKT2 GSK3α 和 GSK3β mRNA 表达，这意味着 AR2B 与胰岛素作用之间存在很强的关系。此外，AR2B 激动剂可能是一种很好的抗糖尿病药物候选者。